Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
Express Scripts Faces Lawsuit Over Arkansas Pharmacy Reimbursement Rates
09/23/2026
Grace Taylor, MS, MA
Arkansas pharmacies allege Express Scripts violated state law by reimbursing prescription claims below required rates.
Arkansas pharmacies allege Express Scripts violated state law by reimbursing prescription claims below required rates.
Arkansas pharmacies allege...
09/23/2026
Pharmacy Learning Network
PharmLaw
Dompé to Pay $32 Million Over Patient Assistance Foundation Kickback Allegations
09/16/2026
Hannah Musick
Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Dompé U.S. has agreed to pay $32...
09/16/2026
Pharmacy Learning Network
PharmLaw
Florida Alleges Express Scripts, Prime Therapeutics Engaged in PBM Reimbursement Price-Fixing
09/09/2026
Hannah Musick
Florida has sued Express Scripts and Prime Therapeutics over allegations that the pharmacy benefit managers (PBMs) unlawfully coordinated pharmacy reimbursement rates, raising new antitrust and compliance questions surrounding PBM contracting...
Florida has sued Express Scripts and Prime Therapeutics over allegations that the pharmacy benefit managers (PBMs) unlawfully coordinated pharmacy reimbursement rates, raising new antitrust and compliance questions surrounding PBM contracting...
Florida has sued Express Scripts...
09/09/2026
Pharmacy Learning Network
PharmLaw
Walmart Reaches $50 Million Settlement Over Opioid Prescription Allegations
09/02/2026
Grace Taylor, MS, MA
Walmart has agreed to pay $50 million to resolve federal allegations that its pharmacies unlawfully filled thousands of opioid and other controlled substance prescriptions.
Walmart has agreed to pay $50 million to resolve federal allegations that its pharmacies unlawfully filled thousands of opioid and other controlled substance prescriptions.
Walmart has agreed to pay $50...
09/02/2026
Pharmacy Learning Network
PharmLaw
Monogram Health to Pay $2.4 Million to Settle Medicare Advantage False Claims Allegations
08/26/2026
Grace Taylor, MS, MA
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to...
08/26/2026
Pharmacy Learning Network

FDA Recalls

News
Dopamine Hydrochloride Injection Recalled Due to Lack of Sterility Assurance
09/24/2026
Rebecca Amrick
Dopamine hydrochloride injection is under a voluntary Class II recall due to the product’s lack of sterility assurance.
Dopamine hydrochloride injection is under a voluntary Class II recall due to the product’s lack of sterility assurance.
Dopamine hydrochloride injection...
09/24/2026
Pharmacy Learning Network
News
Chlorthalidone Tablets Recalled Due to Failed Dissolution Specifications
09/24/2026
Rebecca Amrick
A voluntary Class II recall has been issued for chlorthalidone tablets after the product failed to meet dissolution specifications, a discrepancy that affects 13 567 bottles.
A voluntary Class II recall has been issued for chlorthalidone tablets after the product failed to meet dissolution specifications, a discrepancy that affects 13 567 bottles.
A voluntary Class II recall has...
09/24/2026
Pharmacy Learning Network
News
Thyroid Tablets Recalled Due to Drug Superpotency
09/24/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for thyroid tablets due to drug superpotency, affecting 1955 bottles.
The US Food and Drug Administration (FDA) has issued a Class I recall for thyroid tablets due to drug superpotency, affecting 1955 bottles.
The US Food and Drug...
09/24/2026
Pharmacy Learning Network
News
Povidone and Proparacaine Ophthalmic Solution Recalled Due to Drug Subpotency
09/17/2026
Rebecca Amrick
Povidone iodine and proparacaine hydrochloride ophthalmic solution is under a voluntary Class III recall due to drug subpotency, affecting 772 bottles.
Povidone iodine and proparacaine hydrochloride ophthalmic solution is under a voluntary Class III recall due to drug subpotency, affecting 772 bottles.
Povidone iodine and proparacaine...
09/17/2026
Pharmacy Learning Network
News
Fluphenazine Hydrochloride Tablets Recalled Due to Failed Impurities Specifications
09/17/2026
Rebecca Amrick
A voluntary Class III recall has been issued for fluphenazine hydrochloride tablets after the product failed to meet impurities specifications, a discrepancy that affects 403 200 tablets.
A voluntary Class III recall has been issued for fluphenazine hydrochloride tablets after the product failed to meet impurities specifications, a discrepancy that affects 403 200 tablets.
A voluntary Class III recall has...
09/17/2026
Pharmacy Learning Network

In the News

News
Dopamine Hydrochloride Injection Recalled Due to Lack of Sterility Assurance
09/24/2026
Rebecca Amrick
Dopamine hydrochloride injection is under a voluntary Class II recall due to the product’s lack of sterility assurance.
Dopamine hydrochloride injection is under a voluntary Class II recall due to the product’s lack of sterility assurance.
Dopamine hydrochloride injection...
09/24/2026
Pharmacy Learning Network
News
Chlorthalidone Tablets Recalled Due to Failed Dissolution Specifications
09/24/2026
Rebecca Amrick
A voluntary Class II recall has been issued for chlorthalidone tablets after the product failed to meet dissolution specifications, a discrepancy that affects 13 567 bottles.
A voluntary Class II recall has been issued for chlorthalidone tablets after the product failed to meet dissolution specifications, a discrepancy that affects 13 567 bottles.
A voluntary Class II recall has...
09/24/2026
Pharmacy Learning Network
News
Thyroid Tablets Recalled Due to Drug Superpotency
09/24/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for thyroid tablets due to drug superpotency, affecting 1955 bottles.
The US Food and Drug Administration (FDA) has issued a Class I recall for thyroid tablets due to drug superpotency, affecting 1955 bottles.
The US Food and Drug...
09/24/2026
Pharmacy Learning Network
PharmLaw
Express Scripts Faces Lawsuit Over Arkansas Pharmacy Reimbursement Rates
09/23/2026
Grace Taylor, MS, MA
Arkansas pharmacies allege Express Scripts violated state law by reimbursing prescription claims below required rates.
Arkansas pharmacies allege Express Scripts violated state law by reimbursing prescription claims below required rates.
Arkansas pharmacies allege...
09/23/2026
Pharmacy Learning Network
News
Povidone and Proparacaine Ophthalmic Solution Recalled Due to Drug Subpotency
09/17/2026
Rebecca Amrick
Povidone iodine and proparacaine hydrochloride ophthalmic solution is under a voluntary Class III recall due to drug subpotency, affecting 772 bottles.
Povidone iodine and proparacaine hydrochloride ophthalmic solution is under a voluntary Class III recall due to drug subpotency, affecting 772 bottles.
Povidone iodine and proparacaine...
09/17/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use